Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mic-PtC5Mn is a **PEGylated micelle formulation** containing the manganese-based prodrug PtC5Mn, designed for enhanced anticancer activity. The **mechanism of action** relies on improved delivery and release of the cytotoxic PtC5Mn compound within tumor tissue, resulting in potent antitumoral effects. This formulation demonstrates significantly suppressed tumor growth in vivo compared to PtC5Mn alone, highlighting the advantage of PEGylated micelle-based delivery for improving therapeutic outcomes. mic-PtC5Mn is an experimental agent under investigation for cancer therapy, primarily developed for anticancer indications[6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mic-PtC5Mn.